Latest Administration News

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Lifestyle Communities reported a challenging FY25 with a significant statutory loss driven by a VCAT ruling, yet signs of sales recovery and a refreshed strategy offer a path forward.

Perpetual Limited reported a steady FY25 with underlying profit after tax of $204.1 million, revenue growth across all segments, and a net loss narrowed to $58.2 million. The firm’s refreshed strategy focuses on simplification, operational excellence, and measured growth investments amid evolving regulatory landscapes.

Perpetual Limited reported a steady underlying profit for FY25, achieving significant cost savings while navigating asset management outflows and advancing the sale of its Wealth Management division.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Perpetual Limited reported a resilient FY25 with a slight dip in underlying profit, offset by strong asset growth and progress on its Simplification Program and Wealth Management sale.

Lifestyle Communities reported a significant statutory loss for FY25, driven by legal provisions and asset write-downs, yet signs of recovery emerged in the second half with improved sales and cash flow.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Australian Ethical Investment Limited has delivered a standout FY25 with record funds under management and significant profit growth, setting the stage for its next growth phase.

Australian Ethical Investment Limited reported a robust 68% rise in net profit after tax and a 34% increase in funds under management for FY25, driven by strong organic growth and the Altius acquisition. The company declared a fully franked final dividend of 9 cents per share, underscoring confidence in its growth trajectory.

GLG Corp Ltd reported a reduced net loss of USD 1.35 million for FY2025, improving margins and operational efficiency despite a slight revenue decline. The company closed its Malaysian manufacturing plant and foresees challenges ahead in FY2026.